Longevity.Technology

Longevity.Technology

Publication
0 followers

Daily news and analysis on the longevity market: biotech, research, investment, and therapies.

Loneliness as a Longevity Risk
VideoApr 23, 2026

Loneliness as a Longevity Risk

Gary Brecker, a mortality statistician for insurers, explains that loneliness is a major predictor of reduced lifespan. His research shows that actuarial models can forecast an individual’s remaining years within one to two months, and that loneliness alone can slash...

By Longevity.Technology
$67B Longevity Boom & Big Tech Health Partnerships | Longevity News Roundup — Week 16, 2026
VideoApr 17, 2026

$67B Longevity Boom & Big Tech Health Partnerships | Longevity News Roundup — Week 16, 2026

The episode spotlights a rapidly expanding longevity economy, now projected to reach $67 billion by 2035, driven by consumer demand, expanding clinical pipelines, and a surge of venture capital. Hosts Nina Patrick and Phil Newman dissect how the sector now spans...

By Longevity.Technology
She Was Told MS Was Irreversible… Then She Walked Again
VideoApr 13, 2026

She Was Told MS Was Irreversible… Then She Walked Again

The Longevity Technology Unlocked podcast featured Dr. Terry Walls, a neurologist‑researcher who transformed her own secondary progressive multiple sclerosis (MS) from wheelchair‑bound to walking and biking by combining a rigorously designed paleo diet, targeted supplements, electrical muscle stimulation and strength...

By Longevity.Technology
What Animals Can Teach Us About Reversing Age-Related Disease
NewsApr 7, 2026

What Animals Can Teach Us About Reversing Age-Related Disease

The Longevity Technology Unlocked podcast highlights how studying extreme‑stress animals—such as hibernating ground squirrels and aging dogs—reveals mechanisms that could reverse age‑related disease in humans. Fauna Bio is mining repair pathways in hibernators and translating them to human genomic networks,...

By Longevity.Technology
Cymbiotika Partners with Gary Brecka for Precision Wellness
NewsApr 7, 2026

Cymbiotika Partners with Gary Brecka for Precision Wellness

A wave of strategic collaborations is reshaping the longevity and digital health landscape. Cymbiotika has partnered with wellness futurist Gary Brecka to launch precision‑wellness offerings, while Beacon Biosignals secured more than $97 million in a Series B round. WELL Health announced two...

By Longevity.Technology
Beacon Biosignals Upsizes Series B to More than $97 Million
NewsApr 7, 2026

Beacon Biosignals Upsizes Series B to More than $97 Million

Beacon Biosignals announced that its Series B financing round has been upsized to more than $97 million, well above the originally targeted amount. The round attracted both existing backers and new venture‑capital partners, underscoring confidence in the company’s AI‑driven health‑monitoring platform....

By Longevity.Technology
Generare Bags $21.6m for Nature-Derived Drug Leads
NewsApr 7, 2026

Generare Bags $21.6m for Nature-Derived Drug Leads

Paris‑based biotech Generare closed a €20 million Series A to expand its nature‑derived compound library. The company claims it uncovered more than 200 previously unknown microbial small molecules in 2025, outpacing the rest of the field combined. Generare’s platform scans microbial genomes,...

By Longevity.Technology
New CAR-T Approach May Extend Osteosarcoma Survival
NewsApr 7, 2026

New CAR-T Approach May Extend Osteosarcoma Survival

Researchers at Case Western Reserve University and University Hospitals have engineered a novel CAR‑T cell therapy, OSM CAR‑T, that targets oncostatin M receptors on osteosarcoma cells. Preclinical experiments demonstrated potent in‑vitro killing and significant tumor burden reduction in multiple mouse...

By Longevity.Technology
Allergan Aesthetics Finds Its Next Growth Engine in GLP-1s
NewsApr 7, 2026

Allergan Aesthetics Finds Its Next Growth Engine in GLP-1s

Allergan Aesthetics presented new data at the 2026 AAD meeting linking the surge in GLP‑1 weight‑loss drug use to a growing demand for facial aesthetic treatments. A survey of U.S. clinicians showed that 52% of patients on GLP‑1 agonists express...

By Longevity.Technology
WELL Health Partners with AliveCor for Cardiac Monitoring in Canada
NewsApr 6, 2026

WELL Health Partners with AliveCor for Cardiac Monitoring in Canada

WELL Health announced a partnership with AliveCor to bring the Kardia mobile ECG platform to Canadian patients. The collaboration enables remote cardiac monitoring and real‑time cardiologist review through WELL Health’s telehealth network. By integrating AliveCor’s FDA‑cleared devices, the service aims...

By Longevity.Technology
How Animal Biology Is Shaping The Future of Medicine
VideoApr 6, 2026

How Animal Biology Is Shaping The Future of Medicine

The video explores how evolutionary biology and animal models—particularly companion‑animal gene therapy and hibernation physiology—are being leveraged to accelerate longevity research for humans. Rejuvenate Bio is testing AAV‑based gene therapies in dogs, reporting restored cardiac function, delayed renal decline, and improved...

By Longevity.Technology
Catalyst Precision Health Debuts At-Home Men’s Longevity Care
NewsApr 6, 2026

Catalyst Precision Health Debuts At-Home Men’s Longevity Care

Catalyst Precision Health, a New York startup founded by Mount Sinai physician Dr. Westley Spiro and entrepreneur Matt Renart, has launched what it calls the first men’s longevity service that unites in‑home lab testing, physician house calls, and continuous personalized...

By Longevity.Technology
Agentis, Ultrahuman Tie Wearables to Longevity Care
NewsApr 6, 2026

Agentis, Ultrahuman Tie Wearables to Longevity Care

Agentis Longevity and Ultrahuman have announced a strategic partnership that links Ultrahuman’s wearable biosensor platform with Agentis’ proprietary Longevity Quotient (LQ) score. Continuous glucose monitoring and recovery analytics will feed real‑time data into the LQ, turning a static health snapshot...

By Longevity.Technology
Noom Buys Pharmacy to Push Into Healthy Aging
NewsApr 6, 2026

Noom Buys Pharmacy to Push Into Healthy Aging

Noom, the behavior‑change app best known for weight‑loss coaching, has completed its acquisition of Tailor Made Compounding, a licensed 503A pharmacy operating in 46 U.S. states. The purchase gives Noom direct control over compounding services, enabling it to offer prescription‑grade...

By Longevity.Technology
Longevity Clinics Emerge
VideoApr 5, 2026

Longevity Clinics Emerge

Longevity clinics are emerging as a distinct medical niche, with high‑end facilities and hospital affiliates rebranding under a longevity framework. The segment ranges from rigorously protocol‑driven centers that integrate diagnostics and longitudinal follow‑up to aesthetic and hormone‑focused practices that adopt...

By Longevity.Technology
Cellbricks Secures $10M
VideoApr 4, 2026

Cellbricks Secures $10M

Berlin‑based Celicks announced a $10 million financing round aimed at accelerating its proprietary 3D bioprinting platform for vascularized tissue implants. The capital will fund the transition of its lead programs from pre‑clinical studies into early‑stage clinical trials, positioning the startup at...

By Longevity.Technology
Eli Lilly’s Longevity Bet
VideoApr 3, 2026

Eli Lilly’s Longevity Bet

Eli Lilly is quietly reshaping its R&D agenda, moving from a narrow GLP‑1 obesity play toward a broader longevity strategy. The company’s recent moves signal an ambition to become a “big farmer” of age‑related therapeutics, even if the term does not...

By Longevity.Technology
Early Brain Screening Expands
VideoApr 3, 2026

Early Brain Screening Expands

Premas, a neuro‑tech firm, has announced a partnership with Health is One to roll out its early‑brain‑screening platform across the health‑system network. The initiative focuses on detecting neurodegenerative disease risk factors before patients exhibit any clinical signs. The screening leverages proprietary...

By Longevity.Technology
Curve Bio Strengthens Clinical Push with CMO Hire
NewsApr 3, 2026

Curve Bio Strengthens Clinical Push with CMO Hire

Curve Biosciences, the whole‑body intelligence company, announced the appointment of hepatology expert Dr. Amit Singal as chief medical officer. The hire follows a $40 million financing round and signals the firm’s shift from platform development to clinical implementation, starting with liver...

By Longevity.Technology
Occupational Health Meets Longevity
NewsApr 3, 2026

Occupational Health Meets Longevity

Occupational health is evolving from a compliance‑focused function to a preventive longevity platform, aiming to influence how employees age. Executives are urged to prioritize five key areas, including midlife interventions, data‑driven health monitoring, and navigating privacy challenges. Employers see longevity...

By Longevity.Technology
Can Aging Be Treated Like a Disease? | Longevity News Roundup — Week 14, 2026
VideoApr 3, 2026

Can Aging Be Treated Like a Disease? | Longevity News Roundup — Week 14, 2026

The Longevity Technology Unlocked episode spotlights four converging developments: PMAZ’s partnership with Health is One to roll out an early‑brain‑screening platform, Eli Lilly’s expanding multi‑pathway longevity portfolio, Berlin‑based Cell Bricks securing $10 million for vascularized bioprinted tissue implants, and coordinated global rallies...

By Longevity.Technology
Prediabetes May Need a Tailored Treatment Rethink
NewsApr 3, 2026

Prediabetes May Need a Tailored Treatment Rethink

Researchers presented new data on 662 U.S. adults aged 18‑40 with prediabetes, revealing that the average five‑year risk of progressing to type 2 diabetes is 7.5%. The risk climbs to 10.9% for those meeting GLP‑1 receptor agonist (GLP‑1RA) weight‑loss criteria, 15.1%...

By Longevity.Technology
Superpower Partners with Grail to Add Galleri Cancer Screening
NewsApr 3, 2026

Superpower Partners with Grail to Add Galleri Cancer Screening

Superpower, a technology‑driven health benefits platform, announced a partnership with Grail to incorporate the Galleri multi‑cancer blood test into its member offerings. Galleri screens for more than 50 cancer types using DNA methylation signatures and has received FDA clearance for...

By Longevity.Technology
Well Health Partners with AliveCor for Cardiologist Review
NewsApr 3, 2026

Well Health Partners with AliveCor for Cardiologist Review

Well Health has teamed with AliveCor to embed Canadian‑registered cardiologists into the Kardia app’s AI‑driven ECG workflow. Canadian users can now request a Clinician Review, receiving a written physician interpretation within 24 hours. The service leverages Health Canada‑cleared AI algorithms...

By Longevity.Technology
Designs for Health Launches NeuroCalm Peptide for Gut-Brain Support
NewsApr 3, 2026

Designs for Health Launches NeuroCalm Peptide for Gut-Brain Support

Designs for Health has introduced NeuroCalm Peptide, a once‑daily capsule formulated to support the gut‑brain axis. The product combines the milk‑derived peptide Lactium with heat‑treated Lactobacillus gasseri CP2305, a postbiotic shown to influence stress markers. Clinical data cited by the...

By Longevity.Technology
Annovis Wins US Patent for Buntanetap in Brain Infection Injuries
NewsApr 3, 2026

Annovis Wins US Patent for Buntanetap in Brain Infection Injuries

Annovis Bio has been granted a United States patent for its compound Buntanetap, specifically covering its use in treating brain infection‑related injuries. The patent expands the drug's previously explored Alzheimer’s indication to a novel therapeutic area. This intellectual‑property win bolsters...

By Longevity.Technology
SpectraCell Packages Longevity, Early Disease Detection in One Kit
NewsApr 2, 2026

SpectraCell Packages Longevity, Early Disease Detection in One Kit

SpectraCell Laboratories introduced Baseline Nexus, a bundled diagnostic kit that merges four flagship tests—micronutrient profiling, lipoprotein particle analysis, telomere length measurement, and MTHFR genotyping—into a single service. The package aims to reveal hidden nutrient deficiencies, cardiovascular risk, biological aging, and...

By Longevity.Technology
Rhythm Posts First FDA Approval for Acquired Hypothalamic Obesity
NewsApr 2, 2026

Rhythm Posts First FDA Approval for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) as the first therapy for acquired hypothalamic obesity, covering adults and children aged four and older. The decision follows the Phase 3 TRANSCEND trial, which demonstrated an 18.4% mean BMI reduction versus placebo...

By Longevity.Technology
Annovis Publishes Historical Review of Buntanetap
NewsApr 2, 2026

Annovis Publishes Historical Review of Buntanetap

Annovis released a historical review of its investigational drug Buntanetap in The Scientist, charting its evolution from a 19th‑century execution poison to a modern candidate for Alzheimer’s and Parkinson’s disease. The article details discovery, mechanism elucidation, chemical optimization, and progression...

By Longevity.Technology
Humanaut to Open Dallas Clinic, Launches Founding Membership Presale
NewsApr 2, 2026

Humanaut to Open Dallas Clinic, Launches Founding Membership Presale

Humanaut announced the opening of its first flagship clinic in Dallas, Texas, alongside a founding membership presale. The clinic will deliver metabolic profiling, continuous glucose monitoring, and AI‑driven health coaching under a $5,000 annual membership. The presale targets $10 million to...

By Longevity.Technology
Agentis, Ultrahuman Tie Wearables to Longevity Quotient
NewsApr 2, 2026

Agentis, Ultrahuman Tie Wearables to Longevity Quotient

Agentis Longevity and Ultrahuman announced a strategic partnership to fuse Ultrahuman’s real‑time wearable and continuous glucose monitoring data with Agentis’ proprietary Longevity Quotient (LQ) score. The combined platform will deliver a continuous health score that translates biosensor readings into actionable...

By Longevity.Technology
I-Lumen Receives FDA IDE to Start US I-SIGHT2 Enrollment
NewsApr 2, 2026

I-Lumen Receives FDA IDE to Start US I-SIGHT2 Enrollment

I‑Lumen announced that the U.S. Food and Drug Administration has granted an Investigational Device Exemption (IDE) for its i‑SIGHT2 clinical study. The clearance allows the company to begin enrolling participants in the United States to evaluate its breath‑based metabolic monitoring...

By Longevity.Technology
Kailera Plots IPO to Fuel Obesity Pipeline
NewsApr 1, 2026

Kailera Plots IPO to Fuel Obesity Pipeline

Kailera Therapeutics, after raising $1 billion across a $400 million Series A and $600 million Series B, is preparing an IPO to fund its obesity drug pipeline. Its lead candidate, ribupatide, has delivered up to 23.6% weight loss in Phase 3 injectable trials and 12.1% loss...

By Longevity.Technology
20/20 BioLabs Expands Longevity Test with Kidney Risk Tech
NewsApr 1, 2026

20/20 BioLabs Expands Longevity Test with Kidney Risk Tech

20/20 BioLabs announced an exclusive U.S. license with South Korea’s ROKIT Healthcare to embed its chronic kidney disease (CKD) prediction algorithm into the company’s OneTest for Longevity platform. The addition expands the test beyond inflammation biomarkers to provide early kidney...

By Longevity.Technology
Enlivex Clears Pivotal FDA Hurdle in Knee Osteoarthritis
NewsApr 1, 2026

Enlivex Clears Pivotal FDA Hurdle in Knee Osteoarthritis

Enlivex has secured FDA Investigational New Drug (IND) clearance to launch a global Phase 2b trial of its immunotherapy Allocetra for moderate‑to‑severe age‑related knee osteoarthritis. The study will be randomized, double‑blind, and placebo‑controlled, building on promising Phase 1/2a data from 134 patients....

By Longevity.Technology
Anavex Updates Regulatory Strategy for Blarcamesine
NewsApr 1, 2026

Anavex Updates Regulatory Strategy for Blarcamesine

Anavex Life Sciences has withdrawn its European Union marketing authorization application for blarcamesine and will collect additional data while maintaining dialogue with the European Medicines Agency. The company has concurrently submitted new data to the U.S. FDA to explore a...

By Longevity.Technology
Insilico Medicine, Lilly Partner on AI-Driven Drug Discovery Deal
NewsApr 1, 2026

Insilico Medicine, Lilly Partner on AI-Driven Drug Discovery Deal

Insilico Medicine and Eli Lilly have entered a partnership to use Insilico’s AI‑driven Pharma.AI platform for discovering new oral therapeutics across several disease areas. Lilly receives an exclusive worldwide license to develop, manufacture and commercialize the preclinical candidates, while Insilico secures...

By Longevity.Technology
New Data Show TrenibotE Safety in Repeat Treatments
NewsApr 1, 2026

New Data Show TrenibotE Safety in Repeat Treatments

Allergan Aesthetics presented new Phase 3 data on its investigational neurotoxin TrenibotE at the 2026 American Academy of Dermatology meeting. The open‑label study evaluated up to three repeat glabellar line treatments, confirming a consistent safety profile, no neutralizing antibodies, rapid onset...

By Longevity.Technology
Can Medicine Outrun Aging? Gerontologist Says Odds Are Improving
NewsMar 31, 2026

Can Medicine Outrun Aging? Gerontologist Says Odds Are Improving

Longevity Escape Velocity (LEV) founder Aubrey de Grey discussed the concept of outpacing aging on the Longevity Technology Unlocked podcast. He described LEV as repairing molecular damage to rejuvenate individuals, buying decades for further research, and highlighted mouse studies combining...

By Longevity.Technology
AI-Built Intrabodies Target Alzheimer’s Within
NewsMar 31, 2026

AI-Built Intrabodies Target Alzheimer’s Within

University of Essex researchers used artificial intelligence to redesign antibody fragments, creating "intrabodies" that remain stable inside human cells. By adjusting electrical charge, they converted 672 antibodies into intracellularly functional molecules that bind disease‑causing proteins linked to Alzheimer’s, Parkinson’s, Huntington’s...

By Longevity.Technology
Subtle Antiaging Injectables Become Allergan’s Next Bet
NewsMar 31, 2026

Subtle Antiaging Injectables Become Allergan’s Next Bet

At AMWC 2026, Allergan Aesthetics announced a strategic pivot toward “undetectable” hyaluronic‑acid injectables, emphasizing subtle, personalized maintenance rather than dramatic transformation. The company released a consumer study of 12,000 respondents showing over 70% prefer natural‑looking, reversible results. Allergan frames this...

By Longevity.Technology
Diabetes Eye Damage Linked to Higher Dementia Risk
NewsMar 31, 2026

Diabetes Eye Damage Linked to Higher Dementia Risk

New research published in the American Journal of Ophthalmology tracked nearly 770,000 older adults and found that type 2 diabetes patients with worsening diabetic retinopathy face a markedly higher risk of dementia. Those with the most severe retinal disease had...

By Longevity.Technology
Alterity Receives Positive FDA Feedback on ATH434 Phase 3 Program
NewsMar 31, 2026

Alterity Receives Positive FDA Feedback on ATH434 Phase 3 Program

Alterity Therapeutics received positive written feedback from the U.S. Food and Drug Administration after a Type C meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy. The agency endorsed the company’s clinical pharmacology and non‑clinical development strategy and...

By Longevity.Technology
Private Clinics Face Longevity Learning Curve
NewsMar 30, 2026

Private Clinics Face Longevity Learning Curve

Longevity medicine is moving from niche research into private clinics, where providers are experimenting with layered diagnostics such as genomics, imaging and deep blood panels. The Longevity Show’s new blog outlines the challenges these clinics face, including the lack of...

By Longevity.Technology
PREMAZ Expands Early Brain Screening Through Health Is One
NewsMar 30, 2026

PREMAZ Expands Early Brain Screening Through Health Is One

PREMAZ, a Cambridge‑backed digital cognitive assessment, has partnered with UK wellness provider Health is One to embed early brain‑health screening into everyday well‑being services. The 10‑15 minute test focuses on "memory precision," detecting subtle declines that traditional tests miss. By...

By Longevity.Technology
Global Rallies Call for Aging to Be Treated
NewsMar 30, 2026

Global Rallies Call for Aging to Be Treated

Fund Longevity is staging coordinated rallies in 14 cities to pressure governments into funding geroscience and recognizing aging as a treatable medical condition. The demonstrations underscore a widening gap: private capital is pouring billions into senolytics, cellular reprogramming and AI‑driven...

By Longevity.Technology
Lilly Races to Become First Longevity Big Pharma
NewsMar 30, 2026

Lilly Races to Become First Longevity Big Pharma

Eli Lilly has signed a deal with AI‑focused biotech Insilico Medicine valued up to $2.75 billion, with $115 million paid upfront and the remainder tied to milestones. The agreement grants Lilly an exclusive worldwide license to several preclinical oral candidates and access...

By Longevity.Technology
Allergan Aesthetics Highlights Undetectable Era for HA Injectables
NewsMar 30, 2026

Allergan Aesthetics Highlights Undetectable Era for HA Injectables

Allergan Aesthetics, an AbbVie subsidiary, announced the "undetectable era" for hyaluronic acid (HA) injectables at the Aesthetic & Anti-Aging Medicine World Congress 2026 in Monaco. The company unveiled its global research study, "Layered Beauty: The New Aesthetic Mindset," which highlights...

By Longevity.Technology
Insilico, Tenacia Expand AI-Driven CNS Collaboration
NewsMar 30, 2026

Insilico, Tenacia Expand AI-Driven CNS Collaboration

Insilico Medicine and Tenacia Biotechnology have broadened their AI‑driven collaboration to create additional small‑molecule therapies for central nervous system disorders. Building on a March 2025 program that combined Insilico’s Pharma.AI platform with Tenacia’s proprietary data, the partners will use generative...

By Longevity.Technology